ABUS
Arbutus Biopharma Corporation
NASDAQ · Healthcare · Biotechnology · US
$5.15
+0.59%Aug 21, 2026, 11:30 UTC
Arbutus Biopharma Corporation announced plans to repurchase up to US$230 million of its common shares through a modified Dutch Auction tender offer at a price between US$5.00 and US$5.75 per share, expected to commence on August 24, 2026 and expire on September 29, 2026.
Aug 12, 2026, 11:30 UTC
Arbutus Biopharma reported its financial results for the second quarter of 2026, maintaining a strong financial position with cash, cash equivalents, and marketable securities of $92.6 million as of June 30, 2026.
Source:Aug 6, 2026, 11:00 UTC
Genevant and Arbutus received $950 million from Moderna in July 2026 under a $2.25 billion settlement, with additional $1.3 billion contingent on appeal resolution, and filed new international lawsuits against Pfizer and BioNTech covering 21 jurisdictions.
Source:Jul 16, 2026, 11:30 UTC
Arbutus Biopharma announced its intent to return capital to shareholders.
Source:Jul 16, 2026, 11:30 UTC
Arbutus Biopharma received a first payment from a settlement agreement with Moderna.
Source:Jul 16, 2026, 11:30 UTC
Arbutus Biopharma and its licensee Genevant filed three international patent infringement lawsuits against Pfizer and BioNTech.
Source: